IMMUNOVANT, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
IMMUNOVANT, INC. (IMVT) had Lessee, Operating Lease, Liability, to be Paid, Year One of $141.00 thousand as of 2024-03-31, per its 10-K filed 2024-05-29.
Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2024-05-29
- 2024-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $141.00K.
- 2023-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.20M.
- 2022-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.22M.
- 2021-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.29M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2024-03-31 | $141.00K 10-K · filed 2024-05-29 |
| 2023-03-31 | $1.20M 10-K · filed 2023-05-22 |
| 2022-03-31 | $1.22M 10-K · filed 2022-06-08 |
| 2021-03-31 | $1.29M 10-K · filed 2021-06-01 |
| 2020-12-31 | $1.20M 10-Q · filed 2021-02-16 |
| 2020-09-30 | $1.20M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.20M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |